Health

Hillevax

Private Company

HilleVax is a biopharmaceutical company focused on the development and commercialization of novel vaccine candidates. Its initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection.

hillevax.com

U.S.

Therapeutics

Leaders
Rob Hershberg, MD, PhD

CEO

Aditya Kohli PhD

COO

Astrid Borkowski, MD

CMO

Lightspeed Team

HilleVax is a biopharmaceutical company focused on the development and commercialization of novel vaccine candidates. Its initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection.